Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome, Pfizer Partner on Epigenetics of Stem Cell Differentiation

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemoproteomics firm Cellzome today announced a collaboration with Pfizer to study epigenetic mechanisms involved in stem cell differentiation.

Cellzome will use its Episphere platform to characterize epigenetic changes while Pfizer's Pain & Sensory Disorders and Regenerative Medicine unit, Neusentis, will provide expertise in stem-cell handling and regenerative medicine.

Financial and other terms were not disclosed.

The Episphere technology measures the interaction of drugs with epigenetic targets directly in cells and tissues by capturing a sub-proteome of drug targets and then measuring the effect of the drug.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.